A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...

and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. Breaking Down Genmab's Financial Performance ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

AbbVie (NYSE:ABBV) disclosed:Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2023 are expected to... Effective June 29, 2023, Robert A. Michael has been appointed ...

https://www.tipranks.com/news/the-fly/genmab-says-jj-not-exercising-option-on-hexabody-cd38 Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it ...

With the GEN3014 now removed from the firm’s forecasts, RBC analysts made slight estimate changes in the mid-term and lowered its price target on Genmab shares to DKK 2,300 from DKK 2,400.

Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, equities analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year. Analyst ...

Shares of GMAB stock opened at $20.21 on Tuesday. The stock has a market cap of $13.37 billion, a PE ratio of 11.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a ...

Barclays analyst Emily Field maintained a Buy rating on Genmab A/S (0MGB – Research Report) today and set a price target of DKK2,100.00. The company’s shares closed yesterday at DKK1,382. ...

Truist analyst Asthika Goonewardene lowered the firm’s price target on Genmab (GMAB) to $45 from $50 but keeps a Buy rating on the shares. J&J (JNJ) has opted out of GEN3014, but while this is ...